Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

The Intestinal Microbiome in Infectious Diseases: The Clinical Relevance of a Rapidly Emerging Field.

Harris VC, Haak BW, Boele van Hensbroek M, Wiersinga WJ.

Open Forum Infect Dis. 2017 Jul 8;4(3):ofx144. doi: 10.1093/ofid/ofx144. eCollection 2017 Summer. Review.

2.

Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants.

Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y, Pan Y.

Sci Rep. 2017 Aug 14;7(1):8025. doi: 10.1038/s41598-017-08530-9.

3.

Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

Namasivayam S, Maiga M, Yuan W, Thovarai V, Costa DL, Mittereder LR, Wipperman MF, Glickman MS, Dzutsev A, Trinchieri G, Sher A.

Microbiome. 2017 Jul 7;5(1):71. doi: 10.1186/s40168-017-0286-2.

4.

The microbiome in hematopoietic stem cell transplant recipients and cancer patients: Opportunities for clinical advances that reduce infection.

Koh AY.

PLoS Pathog. 2017 Jun 29;13(6):e1006342. doi: 10.1371/journal.ppat.1006342. eCollection 2017 Jun. No abstract available.

5.

Exploiting CRISPR-Cas to manipulate Enterococcus faecalis populations.

Hullahalli K, Rodrigues M, Palmer KL.

Elife. 2017 Jun 23;6. pii: e26664. doi: 10.7554/eLife.26664.

6.

Topical Antimicrobial Treatments Can Elicit Shifts to Resident Skin Bacterial Communities and Reduce Colonization by Staphylococcus aureus Competitors.

SanMiguel AJ, Meisel JS, Horwinski J, Zheng Q, Grice EA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00774-17. doi: 10.1128/AAC.00774-17. Print 2017 Sep.

PMID:
28630195
7.

Structure and Dimerization of IreB, a Negative Regulator of Cephalosporin Resistance in Enterococcus faecalis.

Hall CL, Lytle BL, Jensen D, Hoff JS, Peterson FC, Volkman BF, Kristich CJ.

J Mol Biol. 2017 Jul 21;429(15):2324-2336. doi: 10.1016/j.jmb.2017.05.019. Epub 2017 May 24.

PMID:
28551334
8.

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen.

Zaza G, Dalla Gassa A, Felis G, Granata S, Torriani S, Lupo A.

PLoS One. 2017 May 24;12(5):e0178228. doi: 10.1371/journal.pone.0178228. eCollection 2017.

9.

Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Lee YJ, Arguello ES, Jenq RR, Littmann E, Kim GJ, Miller LC, Ling L, Figueroa C, Robilotti E, Perales MA, Barker JN, Giralt S, van den Brink MRM, Pamer EG, Taur Y.

J Infect Dis. 2017 Apr 1;215(7):1117-1123. doi: 10.1093/infdis/jix011.

PMID:
28498996
10.

Cooperating Commensals Restore Colonization Resistance to Vancomycin-Resistant Enterococcus faecium.

Caballero S, Kim S, Carter RA, Leiner IM, Sušac B, Miller L, Kim GJ, Ling L, Pamer EG.

Cell Host Microbe. 2017 May 10;21(5):592-602.e4. doi: 10.1016/j.chom.2017.04.002.

PMID:
28494240
11.

Fecal Microbiota Transfer for Multidrug-Resistant Gram-Negatives: A Clinical Success Combined With Microbiological Failure.

Stalenhoef JE, Terveer EM, Knetsch CW, Van't Hof PJ, Vlasveld IN, Keller JJ, Visser LG, Kuijper EJ.

Open Forum Infect Dis. 2017 Mar 13;4(2):ofx047. doi: 10.1093/ofid/ofx047. eCollection 2017 Spring.

12.

Immune Responses to Broad-Spectrum Antibiotic Treatment and Fecal Microbiota Transplantation in Mice.

Ekmekciu I, von Klitzing E, Fiebiger U, Escher U, Neumann C, Bacher P, Scheffold A, Kühl AA, Bereswill S, Heimesaat MM.

Front Immunol. 2017 Apr 19;8:397. doi: 10.3389/fimmu.2017.00397. eCollection 2017.

13.

Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?

Galloway-Peña JR, Jenq RR, Shelburne SA.

Clin Cancer Res. 2017 Jul 1;23(13):3263-3268. doi: 10.1158/1078-0432.CCR-16-3173. Epub 2017 Mar 15.

PMID:
28298544
14.

Roles of the intestinal microbiota in pathogen protection.

Ubeda C, Djukovic A, Isaac S.

Clin Transl Immunology. 2017 Feb 10;6(2):e128. doi: 10.1038/cti.2017.2. eCollection 2017 Feb. Review.

15.

Raising the Alarmone: Within-Host Evolution of Antibiotic-Tolerant Enterococcus faecium.

Van Tyne D, Gilmore MS.

MBio. 2017 Feb 21;8(1). pii: e00066-17. doi: 10.1128/mBio.00066-17.

16.

Suspicion of respiratory tract infection with multidrug-resistant Enterobacteriaceae: epidemiology and risk factors from a Paediatric Intensive Care Unit.

Renk H, Stoll L, Neunhoeffer F, Hölzl F, Kumpf M, Hofbeck M, Hartl D.

BMC Infect Dis. 2017 Feb 21;17(1):163. doi: 10.1186/s12879-017-2251-x.

17.

Long-term use of ceftriaxone sodium induced changes in gut microbiota and immune system.

Guo Y, Yang X, Qi Y, Wen S, Liu Y, Tang S, Huang R, Tang L.

Sci Rep. 2017 Feb 21;7:43035. doi: 10.1038/srep43035.

18.

Subinhibitory Concentrations of Ciprofloxacin Enhance Antimicrobial Resistance and Pathogenicity of Enterococcus faecium.

Sinel C, Cacaci M, Meignen P, Guérin F, Davies BW, Sanguinetti M, Giard JC, Cattoir V.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02763-16. doi: 10.1128/AAC.02763-16. Print 2017 May.

PMID:
28193670
19.

Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome.

Varelias A, Ormerod KL, Bunting MD, Koyama M, Gartlan KH, Kuns RD, Lachner N, Locke KR, Lim CY, Henden AS, Zhang P, Clouston AD, Hasnain SZ, McGuckin MA, Blazar BR, MacDonald KP, Hugenholtz P, Hill GR.

Blood. 2017 Apr 13;129(15):2172-2185. doi: 10.1182/blood-2016-08-732628. Epub 2017 Jan 30.

PMID:
28137828
20.

Characterization of Class IIa Bacteriocin Resistance in Enterococcus faecium.

Geldart K, Kaznessis YN.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02033-16. doi: 10.1128/AAC.02033-16. Print 2017 Apr.

PMID:
28115354

Supplemental Content

Support Center